ORIGYN-FOUNDATION
22.4.2022 18:16:12 CEST | Business Wire | Press release
ORIGYN Foundation, the Swiss non-profit foundation dedicated to identifying, authenticating and unlocking the powers of ownership for objects of value, has announced a partnership with UEFA Foundation for Children. ORIGYN and the UEFA Foundation for Children will partner to create a unique selection of collectibles and NFTs that directly benefits the foundation’s mission to fund children’s rights in areas such as health, education and integration.
As a key component of ORIGYN’s ‘NFTs for Good’ initiative, ORIGYN and UEFA Foundation for Children will create a limited collection of physical collectibles. A corresponding digital twin will be created for each of the one-of-a-kind memorabilia, including one of the toss coins that helped determine the outcome of the UEFA EURO 2020 Final between England and Italy.
“We are thrilled to partner with ORIGYN to bring these important items to the world stage and for the benefit of The UEFA Foundation for Children,” said Urs Kluser, General Secretary for the UEFA Foundation for Children. “We share a united vision of leveraging next-generation technology such as NFTs to raise money for children and world citizens across the globe. There is no better collective mission.”
ORIGYN is the only platform that ties the digital certificate to the world’s most valuable physical artifacts and collectibles. These digital twins are non-fungible, unique and, in many cases, tied to a corresponding physical object. The iconic coin will be minted by ORIGYN into a digital twin NFT and auctioned off together with the physical coin in the second quarter of 2022, alongside other rare collectibles from the foundation.
“We’re incredibly fortunate to have partnered with a foundation that shares a passion for helping children around the world. NFTs are a global technology and should benefit all,” said Daniel Haudenschild , CEO of ORIGYN Enterprise.
This series of unique sports collectibles from the UEFA Foundation for Children, as well as their corresponding digital twin NFTs, will exclusively appear on the ORIGYN-powered consumer marketplace, Impossible Things. Impossible Things will allow collectors to buy, sell and experience unique and authenticated collectibles.
The Impossible Things marketplace will launch in Q2 of 2022 with an Impossible Pass, providing holders priority access to all of the limited collection drops to appear on the marketplace.
“Leveraging ORIGYN’s proprietary technology and the unique consumer-friendly platform at Impossible Things enables us to support causes like The UEFA Foundation for Children, as well as collectors and investors who demand authenticity from the goods they purchase and the cultures that surround them,” said Tom Flanagan, Managing Director of ORIGYN Collectibles.
About the ORIGYN Foundation:
The Swiss non-profit foundation ORIGYN uses intelligent technologies, including computer vision and artificial intelligence, on decentralized computing to identify, authenticate and unlock the powers of ownership for objects of value. As the first digital certification platform built on the Internet Computer (IC), ORIGYN and its verticals generate new forms of value for some of the largest consumer asset classes in the world, including art, collectibles, digital media and luxury goods. Founded in Neuchâtel, Switzerland in October of 2020, ORIGYN operates globally in major technology and blockchain hubs around the world. The foundation’s utility token, OGY, is set to become publicly tradable in the second quarter of 2022. For more information, visit origyn.ch .
ORIGYN Foundation: Website Twitter Telegram LinkedIn Facebook Medium Instagram
For more information about Impossible Things, visit here .
About The UEFA Foundation for Children:
The UEFA Foundation for Children aims to help children and defend their rights, for example through sport and football. It provides support in the areas of health, education, access to sport, personal development, integration of minorities and employability. The Foundation, a public utility body under Swiss law, was created and started its activities on April 24, 2015. The foundation currently invests in 180 projects and has so far funded more than 400 projects in 130 countries worldwide. More than 1.8 million children have already benefited from the foundation's work since its creation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220422005488/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom